Get advice for managing Multiple Sclerosis: Watch the video.

Interferon beta-1b Pregnancy and Breastfeeding Warnings

Interferon beta-1b is also known as: Betaseron, Extavia

Interferon beta-1b Pregnancy Warnings

Animal studies have failed to reveal a teratogenic effect, but abortifacient activity has been demonstrated at higher than recommended doses. There are no controlled data in human pregnancy; however, spontaneous abortions were reported in 4 women during a trial for the treatment of multiple sclerosis. A report of a consensus conference was published in 1996. It states that interferon beta-1b is contraindicated in pregnant or nursing women or those who are actively attempting to become pregnant. Therapy should be stopped in patients who become pregnant while taking interferon beta-1b. It may be most prudent to start (or restart) therapy as soon as possible after delivery or weaning to help decrease the increased risk of exacerbations during the postpartum period. Findings of right incomplete double renal pelvis and ureter in a 1-year-old child is believed to be associated to the interferon therapy used by the mother up to 2.5 months before her pregnancy. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

FDA pregnancy category: C Interferon beta-1b should not be used during pregnancy unless the potential benefit outweighs the potential risk.

Interferon beta-1b Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Interferon beta has been used without apparent harmful effects in the nursing infant.

After using interferon beta-1b for multiple sclerosis throughout pregnancy, a woman continued the drug while exclusively breastfeeding her infant. Regular physician monitoring found the 5-month-old infant was developing well with no abnormalities.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)